Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 2,634 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Not listed Phase 3 Interventional

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

NCT00777244
View directory record Official record
Conditions
Adrenocortical Carcinoma
Interventions
MITOTANE
Drug
Lead sponsor
University of Turin, Italy
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

NCT03695939
View directory record Official record
Conditions
Deep Full-thickness Burn Injury (Disorder)
Interventions
realSKIN (skin xenotransplant), Human Cadaver Allograft
Biological
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Not applicable Interventional

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

NCT03291951
View directory record Official record
Conditions
Resistance Training, Colon Cancer, Chemotherapy Effect
Interventions
Resistance training
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 27, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

NCT02216331
View directory record Official record
Conditions
Tuberculosis
Interventions
TMC207, rifapentine, rifampicin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 27, 2026, 4:51 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

NCT06345339
View directory record Official record
Conditions
Hypothyroidism
Interventions
Armour Thyroid, Levothyroxine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
134
States / cities
Birmingham, Alabama • Bonita, California • Burbank, California + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK

NCT05789173
View directory record Official record
Conditions
Drug-Drug Interaction
Interventions
Methadone and Tizanidine, Efavirenz, Methadone and Tizanidine
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

NCT04274894
View directory record Official record
Conditions
Hypogonadism
Interventions
AndroGel 1.62%
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
45
States / cities
Foley, Alabama • Newport Beach, California • Northridge, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 27, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate the Safety and Clinical Activity of HH2853

NCT04390737
View directory record Official record
Conditions
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Interventions
HH2853 Tablets
Drug
Lead sponsor
Haihe Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

NCT03341013
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MEDI0382 Formulation 2, MEDI0382 Formulation 3
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
23-PPV, 13-PCV Booster, Influenza Vaccine, KLH, OCR, TT Vaccine
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Cullman, Alabama • Tucson, Arizona • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 27, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 27, 2026, 4:51 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

NCT01360450
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine HCL, saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Days to 90 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

NCT03516591
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
AMV564 14-Day CIV
Drug
Lead sponsor
Amphivena Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 27, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

NCT07492160
View directory record Official record
Conditions
Pregnancy, Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
18 Years and older · Female only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Administration of a Bitter-Tasting Medication: Comparison Between the Rx Medibottle and the Oral Syringe

NCT00634374
View directory record Official record
Conditions
Infant Acceptance of Medication
Interventions
Rx Medibottle
Device
Lead sponsor
Bronx-Lebanon Hospital Center Health Care System
Other
Eligibility
2 Days to 24 Months
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Oct 27, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)

NCT07606274
View directory record Official record
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose
Genetic
Lead sponsor
Nuevocor Pte. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 27, 2026, 4:51 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

NCT01721317
View directory record Official record
Conditions
Seizures
Interventions
Ezogabine/Retigabine IR, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
9
States / cities
Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 27, 2026, 4:51 PM EDT
Completed Not applicable Interventional

Comparison of Two Methods of Bowel Preparation for Colonoscopy in Hospitalized Patients

NCT01765491
View directory record Official record
Conditions
Bowel Preparation for Colonoscopy
Interventions
Split-dose polyethylene glycol, Morning-only polyethylene glycol
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 27, 2026, 4:51 PM EDT
Active, not recruiting No phase listed Observational

Diet, Hepcidin, and Chemotherapy RDI

NCT06483997
View directory record Official record
Conditions
Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Endometrial Cancer, Gynecologic Cancer
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 27, 2026, 4:51 PM EDT